Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward commencing in the first half of 2025.” Third Quarter and Recent Program Updates CARDAMYST for patients with paroxysmal supraventricular tachycardia (PSVT) New Drug Application (NDA) for CARDAMYST for PSVT under review by U.S.
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals to Host Investor KOL EventGlobeNewswire
MIST
Earnings
- 11/12/24 - Beat
MIST
Analyst Actions
- 10/14/24 - HC Wainwright
MIST
Sec Filings
- 11/12/24 - Form S-3
- 11/12/24 - Form S-8
- 11/12/24 - Form 8-K
- MIST's page on the SEC website